RetourThis chapter of the operational handbook provides practical advice to complement the latest guideline chapter on drug-resistant TB treatment as part of the WHO consolidated guidelines on tuberculosis and care (hereafter referred to as the “WHO consolidated guidelines”). This document provides information on the choice and design of regimens for the treatment of drug-resistant TB (DR-TB), including multidrug- or rifampicin-resistant TB (MDR/RR-TB), and confirmed rifampicin-susceptible, isoniazid-resistant TB (Hr-TB) (1).
The strategies described in this chapter are based on the latest WHO recommendations (1–3), which were formulated by Guideline Development Groups (GDGs) using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach (4). This chapter complements the guidelines with practical advice based on best practices and knowledge from fields such as pharmacokinetics, pharmacodynamics, microbiology, pharmacovigilance, and clinical and programmatic management. The practical guidance aims to inform the development or revision of national policies and related implementation guidance (e.g. handbooks, standard operating procedures) on the management of DR-TB.